The Parker Institute for Cancer Immunotherapy has provided its class of six early career researchers with a total of almost $3 million for cancer research.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
